

eptinezumab 100mg concentrate for solution for infusion (Vyepti®)

Lundbeck

13 January 2023

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

eptinezumab (Vyepti®) is accepted for restricted use within NHSScotland.

Indication under review: for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

SMC restriction: for patients with chronic and episodic migraine who have had prior failure on three or more migraine preventive treatments.

Eptinezumab provides an additional treatment choice in the therapeutic class of calcitonin gene-related peptide (CGRP) inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 10 January 2023.

Chair

Scottish Medicines Consortium